| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Clinical Trials |
Departments of 1 Radiation Oncology, 2 Neurosurgery, 3 Biostatistics, and 4 Pathology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
We investigated whether increasing levels of tissue hypoxia, measured by the binding of EF5 [2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] or by Eppendorf needle electrodes, were associated with tumor aggressiveness in patients with previously untreated glial brain tumors. We hypothesized that more extensive and severe hypoxia would be present in tumor cells from patients bearing more clinically aggressive tumors. Hypoxia was measured with the 2-nitroimidazole imaging agent EF5 in 18 patients with supratentorial glial neoplasms. In 12 patients, needle electrode measurements were made intraoperatively. Time to recurrence was used as an indicator of tumor aggression and was analyzed as a function of EF5 binding, electrode values and recursive partitioning analysis (RPA) classification. On the basis of EF5 binding, WHO grade 2 tumors were characterized by modest cellular hypoxia (pO2s 
10%) and grade 3 tumors by modest-to-moderate hypoxia (pO2s 10%- 2.5%). Severe hypoxia (0.1% oxygen) was present in 5 of 12 grade 4 tumors. A correlation between more rapid tumor recurrence and hypoxia was demonstrated with EF5 binding, but this relationship was not predicted by Eppendorf measurements.
This article has been cited by other articles:
|
|
 |
|
  A. M. McCord, M. Jamal, U. T. Shankavarum, F. F. Lang, K. Camphausen, and P. J. Tofilon Physiologic Oxygen Concentration Enhances the Stem-Like Properties of CD133+ Human Glioblastoma Cells In vitro Mol. Cancer Res., April 1, 2009; 7(4): 489 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.C. Feldman, D. Chu, M. Schulder, M. Barry, E.-S. Cho, and W.-C. Liu The Blood Oxygen Level-Dependent Functional MR Imaging Signal Can Be Used to Identify Brain Tumors and Distinguish Them from Normal Tissue AJNR Am. J. Neuroradiol., February 1, 2009; 30(2): 389 - 395. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. F. Liu, J. Cai, D. M. Gibo, and W. Debinski Reoxygenation of Hypoxic Glioblastoma Multiforme Cells Potentiates the Killing Effect of an Interleukin-13-Based Cytotoxin Clin. Cancer Res., January 1, 2009; 15(1): 160 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Svensson, J. E. Welch, P. Kucharzewska, P. Bengtson, M. Bjurberg, S. Pahlman, G. B. Ten Dam, L. Persson, and M. Belting Hypoxia-Mediated Induction of the Polyamine System Provides Opportunities for Tumor Growth Inhibition by Combined Targeting of Vascular Endothelial Growth Factor and Ornithine Decarboxylase Cancer Res., November 15, 2008; 68(22): 9291 - 9301. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Das, R. Tsuchida, D. Malkin, G. Koren, S. Baruchel, and H. Yeger Hypoxia Enhances Tumor Stemness by Increasing the Invasive and Tumorigenic Side Population Fraction Stem Cells, July 1, 2008; 26(7): 1818 - 1830. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Spence, M. Muzi, K. R. Swanson, F. O'Sullivan, J. K. Rockhill, J. G. Rajendran, T. C.H. Adamsen, J. M. Link, P. E. Swanson, K. J. Yagle, et al. Regional Hypoxia in Glioblastoma Multiforme Quantified with [18F]Fluoromisonidazole Positron Emission Tomography before Radiotherapy: Correlation with Time to Progression and Survival Clin. Cancer Res., May 1, 2008; 14(9): 2623 - 2630. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Takasawa, R. R. Moustafa, and J.-C. Baron Applications of Nitroimidazole In Vivo Hypoxia Imaging in Ischemic Stroke Stroke, May 1, 2008; 39(5): 1629 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Pore, Z. Jiang, A. Gupta, G. Cerniglia, G. D. Kao, and A. Maity EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1-Independent and HIF-1-Dependent Mechanisms. Cancer Res., March 15, 2006; 66(6): 3197 - 3204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Reardon, J. N. Rich, H. S. Friedman, and D. D. Bigner Recent Advances in the Treatment of Malignant Astrocytoma J. Clin. Oncol., March 10, 2006; 24(8): 1253 - 1265. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Vordermark, S. M. Evans, S. M. Hahn, K. D. Judy, and C. J. Koch Significance of Hypoxia in Malignant Glioma. Re: Evans et al. Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res 2004;10:8177-84 Clin. Cancer Res., May 15, 2005; 11(10): 3966 - 3968. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
